$41.51
Live
1.08%
Downside
Day's Volatility :2.24%
Upside
1.17%
22.24%
Downside
52 Weeks Volatility :40.33%
Upside
23.27%
Period | Vericel Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -19.23% | 3.6% | 0.0% |
6 Months | -8.2% | 10.2% | 0.0% |
1 Year | 24.28% | 19.6% | 0.0% |
3 Years | -17.62% | 16.8% | -23.0% |
Market Capitalization | 2.0B |
Book Value | $4.97 |
Earnings Per Share (EPS) | 0.01 |
PE Ratio | 4067.0 |
PEG Ratio | 0.0 |
Wall Street Target Price | 57.14 |
Profit Margin | 0.37% |
Operating Margin TTM | -11.45% |
Return On Assets TTM | -0.7% |
Return On Equity TTM | 0.36% |
Revenue TTM | 214.5M |
Revenue Per Share TTM | 4.46 |
Quarterly Revenue Growth YOY | 14.7% |
Gross Profit TTM | 109.8M |
EBITDA | 1.2M |
Diluted Eps TTM | 0.01 |
Quarterly Earnings Growth YOY | 1.05 |
EPS Estimate Current Year | 0.1 |
EPS Estimate Next Year | 0.52 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | -0.03 |
What analysts predicted
Upside of 37.65%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 90.9M | ↑ 42.13% |
Net Income | -8.1M | ↓ 52.93% |
Net Profit Margin | -8.96% | ↑ 18.08% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 117.9M | ↑ 29.71% |
Net Income | -7.9M | ↓ 2.8% |
Net Profit Margin | -6.71% | ↑ 2.25% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 124.2M | ↑ 5.37% |
Net Income | 2.9M | ↓ 136.21% |
Net Profit Margin | 2.31% | ↑ 9.02% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 156.2M | ↑ 25.77% |
Net Income | -7.5M | ↓ 360.86% |
Net Profit Margin | -4.78% | ↓ 7.09% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 164.4M | ↑ 5.24% |
Net Income | -16.7M | ↑ 123.65% |
Net Profit Margin | -10.17% | ↓ 5.39% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 197.5M | ↑ 20.17% |
Net Income | -3.2M | ↓ 80.96% |
Net Profit Margin | -1.61% | ↑ 8.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.0M | ↓ 22.16% |
Net Income | -6.3M | ↓ 207.01% |
Net Profit Margin | -15.45% | ↓ 26.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.9M | ↑ 11.96% |
Net Income | -5.0M | ↓ 20.78% |
Net Profit Margin | -10.93% | ↑ 4.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.6M | ↓ 0.74% |
Net Income | -3.7M | ↓ 27.09% |
Net Profit Margin | -8.03% | ↑ 2.9% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 65.0M | ↑ 42.59% |
Net Income | 13.0M | ↓ 455.0% |
Net Profit Margin | 19.99% | ↑ 28.02% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 51.3M | ↓ 21.1% |
Net Income | -3.9M | ↓ 129.72% |
Net Profit Margin | -7.53% | ↓ 27.52% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 52.7M | ↑ 2.69% |
Net Income | -4.7M | ↑ 21.23% |
Net Profit Margin | -8.89% | ↓ 1.36% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 118.7M | ↑ 117.47% |
Total Liabilities | 16.5M | ↓ 48.63% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 153.2M | ↑ 29.11% |
Total Liabilities | 42.1M | ↑ 156.09% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 205.6M | ↑ 34.18% |
Total Liabilities | 71.3M | ↑ 69.28% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 243.7M | ↑ 18.53% |
Total Liabilities | 73.2M | ↑ 2.66% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 273.0M | ↑ 12.02% |
Total Liabilities | 80.7M | ↑ 10.22% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 353.7M | ↑ 29.54% |
Total Liabilities | 127.7M | ↑ 58.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 265.1M | ↓ 2.9% |
Total Liabilities | 71.1M | ↓ 11.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 310.7M | ↑ 17.21% |
Total Liabilities | 111.8M | ↑ 57.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 318.1M | ↑ 2.39% |
Total Liabilities | 113.7M | ↑ 1.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 353.7M | ↑ 11.17% |
Total Liabilities | 127.7M | ↑ 12.27% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 356.7M | ↑ 0.85% |
Total Liabilities | 122.8M | ↓ 3.87% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 376.8M | ↑ 5.66% |
Total Liabilities | 133.9M | ↑ 9.04% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -412.0K | ↓ 96.87% |
Investing Cash Flow | -67.0M | ↑ 4338.87% |
Financing Cash Flow | 58.9M | ↑ 216.86% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.2M | ↑ 1643.45% |
Investing Cash Flow | 10.6M | ↓ 115.84% |
Financing Cash Flow | 5.3M | ↓ 91.06% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.6M | ↓ 344.63% |
Investing Cash Flow | -17.2M | ↓ 261.66% |
Financing Cash Flow | 6.4M | ↑ 22.45% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 29.0M | ↑ 65.26% |
Investing Cash Flow | -3.5M | ↓ 79.6% |
Financing Cash Flow | 9.2M | ↑ 42.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.7M | ↓ 39.09% |
Investing Cash Flow | -36.2M | ↑ 934.16% |
Financing Cash Flow | 1.0M | ↓ 88.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.9M | ↑ 12.69% |
Investing Cash Flow | 2.8M | ↓ 112.89% |
Financing Cash Flow | 107.0K | ↓ 82.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.2M | ↑ 29.72% |
Investing Cash Flow | -2.4M | ↓ 186.0% |
Financing Cash Flow | 1.2M | ↑ 1016.82% |
Sell
Neutral
Buy
Vericel Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Vericel Corporation | -10.16% | -8.2% | 24.28% | -17.62% | 163.17% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Vericel Corporation | 4067.0 | 4067.0 | 0.0 | 0.1 | 0.0 | -0.01 | NA | 4.97 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Vericel Corporation | Buy | $2.0B | 163.17% | 4067.0 | 0.37% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Vericel Corporation
Revenue is up for the last 2 quarters, 51.28M → 52.66M (in $), with an average increase of 2.6% per quarter
Netprofit is down for the last 3 quarters, 12.99M → -4.68M (in $), with an average decrease of 75.5% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 57.4%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 62.4%
BlackRock Inc
Brown Capital Management, LLC
Vanguard Group Inc
State Street Corp
FMR Inc
Conestoga Capital Advisors, LLC
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Organization | Vericel Corporation |
Employees | 314 |
CEO | Mr. Dominick C. Colangelo Esq. |
Industry | Health Technology |
International Select Dividend Ishares
$41.51
-0.36%
Vanguard Ultra Short Bond Et
$41.51
-0.36%
Core Scientific Inc
$41.51
-0.36%
Integer Holdings Corp
$41.51
-0.36%
Liberty Global Plc - Class C Shares
$41.51
-0.36%
Pampa Energia Sa
$41.51
-0.36%
Icf International Inc
$41.51
-0.36%
Pacific Premier Bancorp Inc
$41.51
-0.36%
Arbor Realty Trust, Inc.
$41.51
-0.36%